Celcuity
Clinical-stage biotechnology company that seeks to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* | N/A | $175m | Post IPO Convertible |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | - | 615 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | - | (444 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | (401 %) | (13 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Celcuity is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of various solid tumor indications. The company operates in the oncology market, with a business model centered on its proprietary CELsignia platform. This platform is a functional cellular analysis tool that aims to identify new cancer subtypes and predict the effectiveness of targeted therapies for individual patients, thereby enabling a more personalized approach to cancer treatment.
The company's primary clients are oncologists and clinicians who are seeking more effective treatment options for their patients. By developing companion diagnostics alongside its therapeutic candidates, Celcuity aims to ensure that its drugs are prescribed to the patients who are most likely to benefit. The company is publicly traded and is currently advancing its lead drug candidate, Gedatolisib, through clinical trials for the treatment of breast cancer. Its revenue generation will be dependent on the successful clinical development, regulatory approval, and commercialization of its therapeutic and diagnostic products.
Keywords: biotechnology, oncology, targeted therapies, companion diagnostics, cellular analysis, clinical-stage, solid tumors, personalized medicine, drug development, cancer treatment